Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
 reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Pages:
  • 1
  • 2
  • 3
  • Targeted Therapies in Asthma: KOL Insight (2017)
    Learn More Targeted Therapies in Asthma: KOL Insight (2017)
    As new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala have emerged...
  • Rheumatoid Arthritis: Payer Insight 2016
    Learn More Rheumatoid Arthritis: Payer Insight 2016
    Price war imminent as anti-TNF biosimilars finally hit the US. Get the payer perspective  Manufacturers are gearing up for a price war as biosimilar rheumatoid arthritis (RA) therapies finally hit the US, and...
  • Malignant Melanoma: KOL Insight 2016
    Learn More Malignant Melanoma: KOL Insight 2016
    New combinations emerging as immunotherapies become the backbone therapy Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective...
  • Multiple Sclerosis: KOL Insight 2016
    Learn More Multiple Sclerosis: KOL Insight 2016
    Big changes ahead as Ocrevus nears approval. How will it affect your brand? Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of...
  • Ulcerative Colitis: KOL Insight 2016
    Learn More Ulcerative Colitis: KOL Insight 2016
    Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars;...
  • Colorectal Cancer: KOL Insight 2016
    Learn More Colorectal Cancer: KOL Insight 2016
    KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel...
  • Type 2 Diabetes Mellitus: KOL Insight (2016)
    Learn More Type 2 Diabetes Mellitus: KOL Insight (2016)
    Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists (AACE), but...
  • Prostate Cancer: KOL Insight 2016
    Learn More Prostate Cancer: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with...
  • Chronic Lymphocytic Leukaemia: KOL Insight
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight
    How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will...
  • Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Learn More Non Small Cell Lung Cancer (NSCLC): KOL Insight
    CheckMate-026 results are in. Will Opdivo’s failure open up the field for rival immunotherapies? News that the CheckMate-026 trial failed to meet its primary endpoint has left stakeholders scrambling to sort out...
  • Multiple Sclerosis: Payer Insight
    Learn More Multiple Sclerosis: Payer Insight
    Drug prices rising while needs remain unmet. Now payers are fighting back Payers have had it with the high cost of Multiple Sclerosis (MS) drugs and now they’re fighting back—demanding better data to justify...
  • Psoriasis: KOL Insight
    Learn More Psoriasis: KOL Insight
      Latest Update: Positive results for Phase III CIMPASI and CIMPACT programmes Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of moderate to severe plaque...
  • Age-Related Macular Degeneration (AMD): KOL Insight
    Learn More Age-Related Macular Degeneration (AMD): KOL Insight
    Innovation on all fronts as drug-makers and doctors reimagine wAMD treatment Find out how next-generation VEGF inhibitors and other pipeline drugs will transform wet age-related macular degeneration (wAMD) treatment. Hear...
  • Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    What’s on the KOL ‘wish list’ for the next generation of IPF treatments? Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them?...
  • Multiple Myeloma: KOL Insight
    Learn More Multiple Myeloma: KOL Insight
    Are monoclonal antibodies (mAbs) set to steal the spotlight in MM treatment, despite their expense? Demand persists in haematological oncology for novel, effective modalities that improve outcomes for multiple myeloma (MM)...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Who will benefit most from huge opportunities in NASH treatment? The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which is...
  • Breast Cancer: KOL Insight
    Learn More Breast Cancer: KOL Insight
    Targeted therapies deliver on promise to transform breast cancer treatment Targeted therapies continue to transform breast cancer treatment—branching out into new settings, targeting new patient populations, and in...
  • COPD: KOL Insight
    Learn More COPD: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the COPD market. Topics covered include; Novartis’ December 2016 publication of positive results from the CRYSTAL study,...
  • Dyslipidaemia: KOL Insight
    Learn More Dyslipidaemia: KOL Insight
    Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have relegated them to...
  • Head and Neck Squamous Cell Carcinoma: KOL Insight
    Learn More Head and Neck Squamous Cell Carcinoma: KOL Insight
    Immunotherapies are about to transform HNSCC treatment. Can one brand corner the market? Key opinion leaders (KOLs) say immunotherapies will transform the head and neck squamous cell carcinoma (HNSCC) landscape. But until...
  • Pages:
  • 1
  • 2
  • 3

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved